Rhythm Pharmaceuticals, Inc. (RYTM) News
Filter RYTM News Items
RYTM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RYTM News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RYTM News From Around the Web
Below are the latest news stories about RHYTHM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 -- -- Completed enrollment in supplemental Japanese cohort of Phase 3 trial of setmelanotide in acquired hypothalamic obesity -- -- Completed enrollme |
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potentialJefferies analyst Dennis Ding initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $80 price target The firm sees an 80%-85% probability of success for the company’s Phase III hypothalamic obesity data, which it notes can expand the base business from $500M in peak sales towards $3B. However, expectations are already high and there’s not enough time to fully capitalize and get to peak revenue if the intellectual property expires in 2032, the analyst tells investors in a rese |
Exploring 3 High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 23% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong potential for innovation and adaptability in response to evolving market conditions. |
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three yearsFor us, stock picking is in large part the hunt for the truly magnificent stocks. You won't get it right every time... |
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term PotentialOppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), a developer of treatment for rare obesity disorders. The pharmaceutical industry’s focus on weight management is drawing strong investor interest, with Rhythm Pharmaceuticals standing out for targeting rare obesity disorders that standard treatments often fail to address. The company is steadily growing its business through the global rollout of Imcivree, a drug designed for several genetic obesity conditions. Also Read |
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years OldBOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 |
Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP SecuritiesJMP Securities raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $75 from $64 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Published first on The |
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years OldBOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet- |
Biotech Stock Attempts To End Losing Streak, Lands Back in Buy ZoneThis biotech stock is back in a buy zone after a sharp sell-off. The company makes an obesity drug and develops treatments for rare diseases. |
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity -- BOSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, to |